Mitochondrial-based Therapeutics Market

Mitochondrial-based Therapeutics Market Snapshot (2023 to 2033)

The global mitochondrial-based therapeutics market is expected to be valued at US$ 373.90 million in 2022. Between 2023 and 2033, this market is expected to generate revenues worth US$ 403.06 million and US$ 854.2 million, respectively, with a rapidly rising CAGR of 7.8%.

Inheritable or spontaneous genetic changes in mitochondrial DNA, a small, spherical double-stranded molecule with about 16,400 DNA bases that appear to exist outside of the nucleus, or, in certain cases, nuclear DNA, which negatively affects mitochondrial function, are what are known as mitochondrial diseases.

These illnesses are characterized by genetic, ongoing, and progressive medical symptoms. Certain clinical diseases are uncommon and are known to have an impact on the heart, kidneys, liver, lungs, ears, eyes, pancreas, neurons, and nerves. Hence, the market for mitochondrial-based medicines is anticipated to grow between 2023 and 2033 to effectively treat such illnesses and ailments.

The rising frequency of inherited mitochondrial DNA abnormalities is essentially fueling the mitochondrial myopathies market, which in turn is boosting the mitochondrial-based therapeutics market expansion. Also, the increasing use of numerous drugs, including idebenone, L-carnitine, dichloroacetate, etc., to enhance mitochondrial function and lessen condition-related symptoms is contributing to the market's optimistic outlook. Also, the increased use of biochemical testing, such as enzyme tests, respiratory chain analyses, mitochondrial DNA analyses, etc., to evaluate the mitochondrial function and find anomalies that are indicative of mitochondrial diseases is promoting market expansion.

As per indication, the mitochondrial myopathy segment is expected to dominate the global market. The severity of the illness and the extent of various organ involvement ultimately determine the prognosis of people with mitochondrial myopathies, which can vary substantially. The most often given medications are carnitine and arginine. The cocktail treatment is a coordinated mix of 3-6 medications used by doctors. The market is expected to grow as a result of a rise in the number of cases of mitochondrial myopathies, continuing clinical trials, the aging of the population, more government initiatives, the simplicity of buying, R&D investments by pharmaceutical companies, and the availability of healthcare policies. The clinical study for the nutritional supplement niacin just ended. Opportunities that are anticipated to increase include the development of new screening and diagnostic facilities, the growth of emerging economies in developing nations, and the development of novel medicines.

According to regional projections, North America is anticipated to account for the biggest market share because of improvements in medical and diagnostic capabilities, the accessibility of affordable healthcare facilities, and growing public awareness of mitochondrial illnesses. Due to untapped potential in growing countries, strategic moves by market participants, and the use of genetic analysis to identify mitochondrial problems, Asia Pacific is also anticipated to have the second-largest market share.

In addition to this, several important players are investing heavily in the discovery of biomarkers that can help with the diagnosis and monitoring of the illness, such as serum FGF-21 levels, creatine kinase, coenzyme Q10, etc. This in turn is serving as yet another important component that promotes development. The industry is also being driven forward by the growing acceptance of mitochondrial replacement therapy, a possible therapeutic option that entails replacing a patient's faulty mitochondria with healthy ones from a donor. In addition, the market for mitochondrial-based therapeutics is anticipated to be driven by continuous developments in the field of genetic testing, such as the creation of high-throughput gene sequencing technologies to uncover genetic abnormalities that cause the illness.

Mitochondrial-based Therapeutics Market Overview

Mitochondria present in human cell is responsible for producing 90% of energy in body. Diseases caused by mutations of mitochondrial DNA are treated using mitochondrial-based therapeutics.

Mitochondrial dysfunction contributes many disorders like neurodegeneration, heart failure, metabolic disease or ischemic-reperfusion injury. Mitochondrial-based therapeutics includes mitochondria as a drug target for treatment of chronic, genetic and progressive diseases.

Mitochondrial dysfunction has symptoms like poor growth, muscle weakness, learning disabilities, increased risk of infection, respiratory problem and many more. According to the National Institute of Health (NIH), mitochondrial diseases is most common type of genetic disease with minimum prevalence of greater than 1 in 5000 people across the globe.

Covid-19 has led to a shift of focus for many biopharmaceutical companies to find coronavirus cure, delaying research and development activities in mitochondrial-based therapeutics market.

Manufacturing activities have been put on halt across various unit due to shut down leading reduced growth rate of mitochondrial-based therapeutics market. Reduction in diagnosis and treatment adoption rate owing to decreased patient visits to healthcare facilities is impacting mitochondrial-based therapeutics market.

Rise in prevalence of mitochondrial disorders is expected to increase demand for mitochondrial-based therapeutics market. Increasing collaborative research and development activities among leading biopharmaceutical innovative players is expected to fuel the growth of mitochondrial-based therapeutics market.

For instance in June 2020 Reneo Pharmaceutical’s leading drug candidate REN001 was granted orphan drug designation by the U.S. Food and Drugs Administration for treatment of primary mitochondrial myopathy.

In addition clinical-stage development companies are allocating significant funds towards the development of mitochondrial-based therapeutics market. For instance in October 2019 Alexion Pharmaceuticals and Stealth Biotherapeutics Corp. announced their collaboration to co-develop and commercialize Elamipretide drug used as therapeutic for mitochondrial dysfunction.

Lack of awareness about therapeutic options available for mitochondrial dysfunction is expected to hinder mitochondrial-based therapeutics market growth. Stringent regulatory requirement for drug approval are challenging mitochondrial-based therapeutics market growth.

NSAIDs is expected to hold major revenue share of mitochondrial-based therapeutics market during forecast period. Mitochondrial myopathy created largest revenue share for mitochondrial-based therapeutics market. Leber’s heredity optic neuropathy and Leigh syndrome are forecast to generate significant revenue in mitochondrial-based therapeutics market.

Oral drugs are most commonly used in mitochondrial-based therapeutics market. Whereas hospital pharmacies is a largest distribution channel for mitochondrial-based therapeutics market. Online pharmacies is expected to observe significant growth rate in coming decade with increased rate of adoption.

North America will continue to dominate the mitochondrial-based therapeutics market in the coming decade with a high rate of approvals and commercialization of pharmaceutical drugs. The high rate of prevalence of mitochondrial dysfunctions increases the demand for mitochondrial-based therapeutics market in North America.

Europe is the second leading region in mitochondrial-based therapeutics market with increased investments towards research and development activities. Asia-pacific is lucrative with a higher growth rate in mitochondrial-based therapeutics market during the forecast period with a large patient population in the region.

The Middle East and Africa are expected to observe the least growth in mitochondrial-based therapeutics market due to less healthcare expenditure in the region.

Some key players contributing in mitochondrial-based therapeutics market are

• Pfizer Inc.
• Norvartis AG
• Takeda Pharmaceuticals
• Amgen Inc.
• NeuroVive Pharmaceutical AB
• Entogene AG
• Stealth Biotherapeutics
• Ixchel Pharma
• Reata Pharmaceuticals
• Khondrion BV
• Alkeus Pharmaceuticals
• Intercept Pharmaceutics

Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

The report on mitochondrial-based therapeutics market covers exhaustive analysis on

• Market Segments
• Market Dynamics
• Historical Actual Market Size 2015 to 2019
• Market Size & Forecast 2020 to 2030
• Supply & Demand Value Chain
• Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology
• Value Chain
• Market Drivers and Restraints

Regional analysis for mitochondrial-based therapeutics market includes

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania
• Middle East & Africa

Become a MarketNgage Insider

A unified Market Research Subscription Platform, built for today's disparate research needs.

Sign-Up

Mitochondrial-based Therapeutics Market: Segmentation

The global mitochondrial-based therapeutics market is classified based on drug type, indication, route of administration, distribution channel and region.

Drug Type:

• Anti-inflammatory Biologics
• Non-Steroidal Anti-inflammatory Drugs (NSAIDs)
• Corticosteroids

Indication:

• Mitochondrial Myopathy
• Leber’s heredity Optic Neuropathy
• Leigh Syndrome
• Mitochondrial DNA Depletion Syndrome
• Mitochondrial Encephalomyopathy
• Lactic Acidosis
• Myoclonic Epilepsy with ragged red fibres

Route of Administration:

• Oral 
• Intravenous

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug stores
• Online Pharmacies